Tag: plans

HOUSTON, July 09, 2025 (GLOBE NEWSWIRE) -- APA Corporation (Nasdaq: APA) today provided supplemental information regarding certain second-quarter 2025 financial and operational results. This information is intended only to provide additional information regarding current estimates management believes will affect results for the second-quarter 2025. It is provided to assist investors, analysts and others in formulating their own estimates, and is not intended to be a comprehensive presentation of all factors that will affect second-quarter 2025 results. Actual results and the impact of factors identified here may vary depending on the impact of other factors not identified here and are subject to finalization of the financial reporting process for second-quarter 2025.

HOUSTON, July 09, 2025 (GLOBE NEWSWIRE) -- Crown Castle Inc. (NYSE: CCI) ("Crown Castle") plans to release its second quarter 2025 results on Wednesday, July 23, 2025, after the market closes. In conjunction with the release, Crown Castle has scheduled a conference call for Wednesday, July 23, 2025, at 5:30 p.m. eastern time.

MIAMI, July 09, 2025 (GLOBE NEWSWIRE) -- Motorsport Games Inc. (NASDAQ: MSGM) (“Motorsport Games” or “the Company”) is today reporting on reaching key operational milestones for Le Mans Ultimate, the official game of the FIA World Endurance Championship and the 24 Hours of Le Mans, and RaceControl, the Company’s matchmaking and online racing system, which provides enhanced access to online features, including championships, extended registration periods, and priority driver reports.

Data from Orbit and Cosmic studies expected around the end of the year

Daix (France), New York City (New York, United States), July 9, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced a leadership transition with the appointment of Jason Campagna, MD, PhD, as President of Research and Development (“R&D”) and Chief Medical Officer (“CMO”) and Martine Zimmermann, PharmD, as Executive Vice President (“EVP”) of Regulatory Affairs and Quality Assurance.

Daix (France), New York City (New York, États-Unis), le 9 juillet 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé aujourd'hui une transition au sein de son équipe de direction avec la nomination de Jason Campagna, MD, PhD, en tant que Président de la Recherche et du Développement (« R&D ») et Directeur Médical (« CMO »), ainsi que Martine Zimmermann, PharmD, en tant que Vice-Présidente Exécutive (« EVP ») en charge des affaires réglementaires et de l’ assurance qualité.